ClinicalTrials.gg
CompletedNCT01024608Updated Dec 3, 2021Results posted

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

A Phase 3 interventional study of Beclomethasone dipropionate and Placebo Nasal Aerosol in Seasonal Allergic Rhinitis and Hay Fever, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 4 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-12-03.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · United States.

Enrollment
56th of 101
340 · median 446
Started
2009
with 12 others
Phase 3
47 of 107
none open now
Registered
65th of 107
by date
Lead sponsor
4 of 107
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, this one is the 56th largest by enrollment of the 101 interventional ones that give a count, is one of 13 that started in 2009, is one of 47 in phase 3, and was the 65th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

1 of the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis.

03

Conditions studied

  • Seasonal Allergic Rhinitis
  • Hay Fever
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 12 years of age or older
  • Documented history of season allergic rhinitis to mountain cedar pollen
  • General good health
  • Other criteria apply

Exclusion criteria

Exclusion Criteria:

  • History of physical findings of nasal pathology (within 60 days prior to screening visit)
  • Participation in any drug study 30 days preceding screening visit
  • History of respiratory infection/disorder with 14 days preceding screening visit
  • Use of any prohibited concomitant medications
  • Other criteria apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
340 participants (actual)

Study arms

  • Experimental
    BDP HFA 320 µg/day

    During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.

    Drug: Beclomethasone dipropionate

  • Placebo comparator
    Placebo

    During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.

    Drug: Placebo Nasal Aerosol

Interventions

  • Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.

    Also known as: QNASL(TM)

  • DrugPlacebo Nasal Aerosol

    Placebo nasal aerosol administered each morning for two weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, nasal itching and nasal congestion) over the past 12 hours (prior to the assessment) twice daily (AM and PM) using the following scale: 0=absent (no sign/symptom present); 1=mild (sign/symptom present, easily tolerated); 2=moderate (definite awareness of sign/symptom, bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities and/or sleeping). The rTNSS (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates symptom improvement.

    Time frame: Baseline (Days -3 to 0), and Days 1-15

Secondary outcomes

  1. Change From Baseline in Average Subject-Reported AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, nasal itching and nasal congestion) over the past 10 minutes (prior to the assessment) twice daily (AM and PM) using the following scale: 0=absent (no sign/symptom present); 1=mild (sign/symptom present, easily tolerated); 2=moderate (definite awareness of sign/symptom, bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The iTNSS (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates symptom improvement.

    Time frame: Baseline (Days -3 to 0), and Days 1-15

  2. Change From Baseline at Week 2 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline

    The adult RQLQ has 28 questions in 7 domains. Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Not Troubled to 6 = Extremely Troubled) for the domains of activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, and eye symptoms. The domain of 'emotional' utilized a separate scale (0 = None of the time to 6 = All of the time). The overall RQLQ score is the mean of all 28 responses. Week 2 scores were compared to baseline scores. A negative change from baseline score indicates improvement.

    Time frame: Day 0 (Baseline), Day 15

  3. Change From Baseline in AM and PM Subject-reported Reflective Ocular Symptom Score Over the 2-week Treatment Period

    Participants recorded the severity of their ocular symptoms (Itching/burning eyes, tearing/watering eyes, and redness of eyes) over the past 12 hours (prior to the assessment) twice daily (AM and PM) using the following scale: 0=absent (no sign/symptom present); 1=mild (sign/symptom present, easily tolerated); 2=moderate (definite awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities). The total ocular symptom score ranges from 0 to 9 (worst symptoms). A negative change from baseline score indicates improvement.

    Time frame: Baseline (Days -3 to 0), and Days 1-15

07

Results

Posted May 23, 2012

Participant flow

A total of 484 patients were screened and 463 patients were enrolled in the study and participated in the Run-in Period. Of the 463 enrolled patients, 340 were randomized to study treatment.

Participant flow — Overall Study
MilestoneBDP HFA 320 µg/DayPlacebo
Started169171
Intent to treat population167171
Safety population167171
Completed165167
Not completed44
Withdrew: Adverse event10
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up01
Withdrew: Protocol violation03
Withdrew: Never received study treatment20

Outcome measures

PrimaryChange From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, nasal itching and nasal congestion) over the past 12 hours (prior to the assessment) twice daily (AM and PM) using the following scale: 0=absent (no sign/symptom present); 1=mild (sign/symptom present, easily tolerated); 2=moderate (definite awareness of sign/symptom, bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities and/or sleeping). The rTNSS (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates symptom improvement.

Time frame:
Baseline (Days -3 to 0), and Days 1-15
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period-2.0 ± 0.16-1.0 ± 0.15
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = <0.001 (A priori threshold for statistical significance is p\<0.05.) · Ls mean treatment diff from placebo: -0.91 · 95% CI -1.3 to -0.5Repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in Average Subject-Reported AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, nasal itching and nasal congestion) over the past 10 minutes (prior to the assessment) twice daily (AM and PM) using the following scale: 0=absent (no sign/symptom present); 1=mild (sign/symptom present, easily tolerated); 2=moderate (definite awareness of sign/symptom, bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The iTNSS (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates symptom improvement.

Time frame:
Baseline (Days -3 to 0), and Days 1-15
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average Subject-Reported AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average Subject-Reported AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period-1.7 ± 0.15-0.8 ± 0.15
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = <0.001 (A priori threshold for statistical significance is p\<0.05) · Ls mean treatment diff from placebo: -0.92 · 95% CI -1.3 to -0.5The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline at Week 2 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline

The adult RQLQ has 28 questions in 7 domains. Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Not Troubled to 6 = Extremely Troubled) for the domains of activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, and eye symptoms. The domain of 'emotional' utilized a separate scale (0 = None of the time to 6 = All of the time). The overall RQLQ score is the mean of all 28 responses. Week 2 scores were compared to baseline scores. A negative change from baseline score indicates improvement.

Time frame:
Day 0 (Baseline), Day 15
Reported as:
Least squares mean · units on a scale
Change From Baseline at Week 2 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline at Week 2 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline-1.2 ± 0.12-0.8 ± 0.12
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = 0.005 (A priori threshold for statistical significance is p\<0.05) · Ls mean treatment diff from placebo: -0.48 · 95% CI -0.8 to -0.1Results obtained from ANCOVA with treatment, baseline and center in the model.
SecondaryChange From Baseline in AM and PM Subject-reported Reflective Ocular Symptom Score Over the 2-week Treatment Period

Participants recorded the severity of their ocular symptoms (Itching/burning eyes, tearing/watering eyes, and redness of eyes) over the past 12 hours (prior to the assessment) twice daily (AM and PM) using the following scale: 0=absent (no sign/symptom present); 1=mild (sign/symptom present, easily tolerated); 2=moderate (definite awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities). The total ocular symptom score ranges from 0 to 9 (worst symptoms). A negative change from baseline score indicates improvement.

Time frame:
Baseline (Days -3 to 0), and Days 1-15
Reported as:
Least squares mean · units on a scale
Change From Baseline in AM and PM Subject-reported Reflective Ocular Symptom Score Over the 2-week Treatment Period
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in AM and PM Subject-reported Reflective Ocular Symptom Score Over the 2-week Treatment Period-1.3 ± 0.13-0.7 ± 0.12
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = 0.002 (A priori threshold for statistical significance is p\<0.05) · Ls mean treatment diff from placebo: -0.56 · 95% CI -0.9 to -0.2The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BDP HFA 320 µg/Day—1/167 (0.6%)11/167 (6.6%)
Placebo—0/171 (0%)10/171 (5.8%)
Most frequent serious events
Most frequent serious events
EventBDP HFA 320 µg/DayPlacebo
Hypertensive crisisVascular disorders1/1670/171
Most frequent other events
Most frequent other events
EventBDP HFA 320 µg/DayPlacebo
Nasal discomfortRespiratory, thoracic and mediastinal disorders11/16710/171

Baseline characteristics

Age, Continuous
Age, Continuous(years)BDP HFA 320 µg/DayPlaceboTotal
Mean39.3 ± 13.438.0 ± 13.338.6 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)BDP HFA 320 µg/DayPlaceboTotal
Female11397210
Male5474128
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BDP HFA 320 µg/DayPlaceboTotal
Hispanic or Latino5249101
Not Hispanic or Latino115122237
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP HFA 320 µg/DayPlaceboTotal
American Indian or Alaska Native112
Asian336
Native Hawaiian or Other Pacific Islander011
Black or African American232649
White142142284
08

Study locations

4 sites
  • Teva Clinical Trial Site
    Austin, Texas 78731, United States
  • Teva Clinical Trial Site
    New Braunfels, Texas 78130, United States
  • Teva Clinical Trial Site
    San Antonio, Texas 78229, United States
  • Teva Clinical Trial Site
    Waco, Texas 76712, United States
09

References and documents

Publications

  • Van Bavel J, Ratner PH, Amar NJ, Hampel FC, Melchior A, Dunbar SA, Tantry SK and Dorinsky PM (2011). BDP HFA Nasal Aerosol 320 μg Once Daily Effectively Improves Ocular Symptoms Associated With Seasonal Allergic Rhinitis. Ann Allergy Asthma Immunol. 107(11):A118.
  • Van Bavel J, Dorinsky PM, Melchior A, Dunbar SA, and Tantry SK (2011). Nasal Symptom Relief and Improvement in Health-Related Quality of Life Following Treatment with BDP HFA Nasal Aerosol (320 mcg Once Daily) in Subjects with Seasonal Allergic Rhinitis. Allergy Asthma Proc. 32(4):330.
  • Van Bavel J, Hampel, FC, Ratner PH, Melchior A, Dunbar SA, Tantry SK and Dorinsky PM (2011). BDP HFA Nasal Aerosol Effectively Improves Nasal Symptom Relief and Health-Related Quality of Life (QOL) in Subjects with Seasonal Allergic Rhinitis (SAR). J Allergy Clin Immunol. 127(2):201.
  • Van Bavel J, Amar NJ, Melchior A, Dunbar SA, Tantry SK and Dorinsky PM (2010).BDP HFA Nasal Aerosol, 320 mcg Once Daily, is Safe and Effective in the Treatment of Nasal Symptoms Associated with Seasonal Allergic Rhinitis (SAR). Ann Allergy Asthma Immunol. 105(5):121.
  • van Bavel JH, Ratner PH, Amar NJ, Hampel FC Jr, Melchior A, Dunbar SA, Dorinsky PM, Tantry SK. Efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2012 Sep-Oct;33(5):386-96. doi: 10.2500/aap.2012.33.3593. PubMed 23026180 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2009 to primary completion in Feb 2010, 1 month.

Results were first posted in May 2012, 2 years 2 months after primary completion. A results delay was requested in Aug 2011.

Of 31 industry-sponsored phase 3 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 1 month is below that.

Counting every sponsor, half of 37 studies reached it within 4 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2009
First posted
Dec 3, 2009
StartActual
Dec 31, 2009
Primary completionActual
Feb 28, 2010
CompletionActual
Feb 28, 2010
Results delay requested
Aug 25, 2011
Results first posted
May 23, 2012
Last update
Dec 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01024608
Responsible party
Sponsor
First posted
Dec 3, 2009
Start date
Dec 31, 2009
Primary completion
Feb 28, 2010
Completion
Feb 28, 2010
Results posted
May 23, 2012
Last update
Dec 3, 2021

Study contacts

Sudeesh Tantry, Ph.D.
study director · Teva Branded

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion